Harm Westdorp

1.5k citations
44 papers · 764 · 1 hit paper · h-index 14

Impact in

  • Oncology top 5%
    • Cancer Immunotherapy and Biomarkers
    • Peptidase Inhibition and Analysis
    • CAR-T cell therapy research
  • Immunology top 10%
    • Immunotherapy and Immune Responses
    • Immune Cell Function and Interaction

Papers in

Harm Westdorp

39 papers receiving 756 citations

Harm Westdorp's Hit Papers

Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies 2023 · 114 citations
1140+1+2Years since publication255075100

Peers

Harm Westdorp
Comparison fields: 5 of 60
  • Oncology 425
  • Immunology 248
  • Cancer Research 94
  • Pathology and Forensic Medicine 85
  • Radiology, Nuclear Medicine and Imaging 96
Replace Claudio Dansky Ullmann with:
Claudio Dansky Ullmann United States
Hoiseon Jeong South Korea
María Villalba Spain
Charles Schweizer United States
W.E. Gillanders United States
Christina Williamson United States
Els Van Nieuwenhuysen Belgium
Federico Sandoval France
Masato Sugano Japan
Arthur Liu United States
Harm Westdorp relative to Claudio Dansky Ullmann United States Claudio Dansky Ullmann's profile →
Citations per field
00.5×
Claudio Dansky Ullmann · 1×
Citations per year

Countries citing papers authored by Harm Westdorp

Since Specialization
Citations

This map shows the geographic impact of Harm Westdorp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Harm Westdorp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Harm Westdorp more than expected).

Fields of papers citing papers by Harm Westdorp

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Harm Westdorp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Harm Westdorp. The network helps show where Harm Westdorp may publish in the future.

Co-authors

The 25 scholars most cited alongside Harm Westdorp, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Harm Westdorp Line = papers co-authored together Harm Westdorp links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 44 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies
Hit paper breakdown →
2023114
2 201989
3 201671
4 201471
5 201746
6 202243
7 202134
8 202134
9 201832
10 201630
11 201621
12 202318
13 201818
14 202415
15 202312
16 202412
17 201611
18 202310
19 201410
20 202110

About Harm Westdorp

Harm Westdorp is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Immunology, Molecular Biology and Pathology and Forensic Medicine, having authored 44 papers that have together received 764 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (15 papers), Prostate Cancer Treatment and Research (12 papers), Immunotherapy and Immune Responses (10 papers), Genetic factors in colorectal cancer (7 papers), Cancer Genomics and Diagnostics (5 papers), Colorectal Cancer Treatments and Studies (4 papers), vaccines and immunoinformatics approaches (3 papers) and Immune Cell Function and Interaction (2 papers). The work is most often cited by research in Oncology (425 citations), Immunology (248 citations), Cancer Research (94 citations), Pathology and Forensic Medicine (85 citations) and Radiology, Nuclear Medicine and Imaging (96 citations). Harm Westdorp has collaborated with scholars based in Netherlands, United States and Germany. Frequent co-authors include I. Jolanda M. de Vries, Gerty Schreibelt, Winald R. Gerritsen, Carl G. Figdor, Niven Mehra, Sandra Heskamp, James Nagarajah, Bastiaan M. Privé, Steffie M. B. Peters and Willemijn A. van Gemert. Their work appears in journals such as Annals of Oncology, Frontiers in Immunology, Journal of Clinical Oncology, Frontiers in Oncology and Journal for ImmunoTherapy of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact